No Data
Express News | Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18
Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Cuts Target Price to $13.54
Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $20
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)
Cathie Wood's Weekly Recap: Buys TEM, WGS, and CRWV; Sells AMD and RKLB
Analysts Expect Breakeven For Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Before Long